Dose painting in radiotherapy for head and neck squamous cell carcinoma: Value of repeated functional imaging with 18F-FDG PET, 18F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI

Journal of Nuclear Medicine

Volumn 50, Issue 7, 2009, Pages 1020-1027

  Dirix, Piet ^a   Vandecaveye, Vincent ^a   De Keyzer, Frederik ^a   Stroobants, Sigrid ^a   Hermans, Robert ^a   Nuyts, Sandra ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Head and neck cancer; MRI; PET; Radiotherapy

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CISPLATIN; FLUORODEOXYGLUCOSE F 18; GADOBENATE DIMEGLUMINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIFFUSION WEIGHTED IMAGING; DISEASE FREE SURVIVAL; DOSIMETRY; DRUG UPTAKE; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; LYMPH NODE METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; DOSE FRACTIONATION; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 67650075036     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.062638     Document Type: Article

References (40)

1. Galvin JM, De Neve W. Intensity modulating and other radiation therapy devices for dose painting. J Clin Oncol. 2007;25:924-930.
2. Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy: biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551-560.
3. Nuyts S. Defining the target for radiotherapy of head and neck cancer. Cancer Imaging. 2007;7(suppl):S50-S55.
4. Grégoire V, Haustermans K, Geets X, Roels S, Lonneux M. PET-based treatment planning in radiotherapy: a new standard? J Nucl Med. 2007;48(suppl):68S-77S.
5. Daisne J-F, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG-PET and validation with surgical specimen. Radiology. 2004;233:93-100.
6. Schwartz DL, Ford E, Rajendran J, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:129-136.
7. Schwartz DL, Ford EC, Rajendran J, et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head Neck. 2005;27:478-487.
8. Madani I, Duthoy W, Derie C, et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;68:126-135.
9. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18] fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
10. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435-5441.
11. Thorwarth D, Eschmann S-M, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys. 2007;68:291-300.
12. Lee NY, Mechalakos JG, Nehmeh S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2008;70:2-13.
13. Le Bihan D. Molecular diffusion, tissue microdynamics and microstructure. NMR Biomed. 1995;8:375-386.
14. Vandecaveye V, De Keyzer F, Nuyts S, et al. Detection of head and neck squamous cell carcinoma with diffusion-weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys. 2007;67:960-971.
15. Vandecaveye V, De Keyzer F, Vander Poorten V, et al. Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology. 2009;251:131-146.
16. Dirix P, De Keyzer F, Vandecaveye V, Stroobants S, Hermans R, Nuyts S. Diffusion-weighted magnetic resonance imaging to evaluate major salivary gland function before and after radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 71:1365-1371.
17. Patterson DM, Padhani AR, Collins DJ. Technology insight: water diffusion MRI - a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol. 2008;5:220-233.
18. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging. 2002;16:407-422.
19. Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumor response to radiotherapy. Lancet Oncol. 2007;8:63-74.
20. Nuyts S, Dirix P, Clement PM, et al. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2009;73:1088-1095.
21. Daisne J-F, Sibomana M, Bol A, Doumont T, Lonneux M, Grégoire V. Tridimensional automatic segmentation of PET volumes based on measured sourceto-background ratios: influence of reconstruction algorithms. Radiother Oncol. 2003;69:247-250.
22. Rajendran JG, Krohn KA. Imaging tumor hypoxia. In: Bailey DL, Townsend DW, Valk PE, Maisey MN, eds. Positron Emission Tomography, Principles and Practice. London, U.K.: Springer-Verlag; 2002.
23. Dirix P, Nuyts S, Vanstraelen B, et al. Post-operative intensity-modulated radiotherapy for malignancies of the nasal cavity and paranasal sinuses. Radiother Oncol. 2007;85:385-391.
24. Geets X, Tomsej M, Lee JA, et al. Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy. Radiother Oncol. 2007;85:105-115.
25. Rasch C, Keus R, Pameijer FA, et al. The potential impact of CT-MRI matching on tumor volume delineation in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1997;39:841-848.
26. Geets X, Daisne J-F, Arcangeli S, et al. Inter-observer variability in the delineation of pharyngo-laryngeal tumor, parotid glands and cervical spinal cord: comparison between CT-scan and MRI. Radiother Oncol. 2005;77:25-31.
27. 18F]-fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295-1300.
28. Schwartz DL, Rajendran J, Yueh B, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg. 2004;130:1361-1367.
29. Vernon MR, Maheshwari M, Schultz CJ, et al. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys. 2008;70:678-684.
30. Soto DE, Kessler ML, Piert M, Eisbruch A. Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. Radiother Oncol. 2008;89:13-18.
31. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: an international multi-center study. Radiother Oncol. 2005;77:18-24.
32. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253-260.
33. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006;24:2098-2104.
34. 18F-misonidazole and PET: changes of kinetics during radiotherapy of head-andneck cancer. Radiother Oncol. 2007;83:406-410.
35. Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys. 2002;54:921-927.
36. 18F- fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys. 2007;68:515-521.
37. 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys. 2008;70:1219-1228.
38. Hamstra DA, Lee KC, Moffat BA, et al. Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol. 2008;1:187-194.
39. Pickles MD, Manton DJ, Lowry M, Turnbull LW. Prognostic value of pretreatment DCE-MRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy. Eur J Radiol. June 20, 2008 [Epub ahead of print].
40. Hermans R, Meijerink M, Van den Bogaert W, Rijnders A, Weltens C, Lambin P. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:1351-1356.